Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 35Uveal Melanoma 9Prostatic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Skin Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Lung Neoplasms 1Leukemia 1Fallopian Tube Neoplasms 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1

Interventions

Sunitinib 4Everolimus 4Fluorouracil 3Temozolomide 2Streptozocin 2Octreotide 2Leucovorin 2Irinotecan 2sargramostim 1sapanisertib 1pasireotide 1napabucasin 1motesanib diphosphate 1montanide ISA 51 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1ibrutinib 1ganitumab 1cabozantinib 1batifiban 1aflibercept 1Wound Healing 1Thalidomide 1Taxes 1Sorafenib 1Salts 1Plastic Surgery Procedures 1Paclitaxel 1Oxaliplatin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenoma, Islet Cell × incomplete Freund's adjuvant × Clear all
NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡